Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Imipramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 13/20 | 0.71 |
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.71 |
| ▸ | HRH1 | P35367 | 5/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | MAPT | P10636 | 3/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.71 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.71 |
| ▸ | DRD2 | P14416 | 3/20 | 0.71 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.71 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.71 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.71 |
| ▸ | HTR2A | P28223 | 3/20 | 0.71 |
| ▸ | HTR2C | P28335 | 3/20 | 0.71 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.71 |
| ▸ | DRD3 | P35462 | 3/20 | 0.71 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.71 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.71 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.71 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imipramine SCHEMBL2822806 | 0.88 | SLC6A4 (0.58) | SLC6A4HRH1LMNAMAPTADORA3 | |
| Imipramine SCHEMBL20644144 | 0.87 | SLC6A4 (0.83) | SLC6A4HRH1LMNAMAPTADORA3 | |
| Imipramine SCHEMBL6118138 | 0.84 | SLC6A4 (1.00) | SLC6A4HRH1LMNAMAPTADORA3 | |
| Imipramine SCHEMBL29350100 | 0.84 | SLC6A4 (1.00) | SLC6A4HRH1LMNAMAPTADORA3 | |
| Imipramine SCHEMBL34282 | 0.84 | SLC6A4 (1.00) | SLC6A4HRH1LMNAMAPTADORA3 | |
| Imipramine SCHEMBL17004048 | 0.84 | SLC6A4 (1.00) | SLC6A4HRH1LMNAMAPTADORA3 | |
| Imipramine SCHEMBL3002524 | 0.84 | SLC6A4 (0.76) | SLC6A4HRH1LMNAMAPTADORA3 | |
| Imipramine SCHEMBL3002526 | 0.84 | SLC6A4 (0.76) | SLC6A4HRH1LMNAMAPTADORA3 | |
| Imipramine SCHEMBL2098515 | 0.83 | LMNA (0.62) | SLC6A4HRH1LMNAMAPTADORA3 | |
| Imipramine SCHEMBL41765 | 0.83 | LMNA (1.00) | SLC6A4HRH1LMNAMAPTADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575151-B1 | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance | Pisgah National Laboratories, Inc. (US) | 2013-11-05 | — | — | US | claimed |
| US-20090259039-A1 | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance | PISGAH LABORATORIES, INC. | 2009-10-15 | — | — | US | claimed |
| US-20080293695-A1 | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance | PISGAH LABORATORIES, INC. | 2008-11-27 | — | — | US | claimed |
| US-9421266-B2 | Safety of pseudoephedrine drug products | PISGAH LABORATORIES, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-8883863-B1 | Safety of psuedoephedrine drug products | PISGAH LABORATORIES, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8859622-B1 | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance | PISGAH LABORATORIES, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20140178480-A1 | SAFETY OF PSUEDOEPHEDRINE DRUG PRODUCTS | PISGAH LABORATORIES, INC. | 2014-06-26 | — | — | US | disclosed |
| US-8575151-B1 | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance | Pisgah National Laboratories, Inc. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8334322-B1 | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance | Pisgah Laboratories, LLC (US) | 2012-12-18 | — | — | US | disclosed |
| US-20090259039-A1 | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance | PISGAH LABORATORIES, INC. | 2009-10-15 | — | — | US | disclosed |
| US-20080293695-A1 | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance | PISGAH LABORATORIES, INC. | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293695-A1 | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance | SLC6A2, SLC18A2, SLC6A3 | SLC6A4 7/4885SLC6A2 1/4885HRH1 584/4885 |
| US-20140178480-A1 | SAFETY OF PSUEDOEPHEDRINE DRUG PRODUCTS | SORD, ABCB11, ABCB1 | SLC6A4 126/4885SLC6A2 31/4885HRH1 980/4885 |
| US-20090259039-A1 | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance | SLC18A2, SLC18A1, SLC6A2 | SLC6A4 12/4885SLC6A2 3/4885HRH1 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.